Key facts
- This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for TELA Bio, Inc. (TELA).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 02 Jul 2024, 16:54.
ORBIMED ADVISORS LLC - 28 Jun 2024 Form 4 Insider Report for TELA Bio, Inc. (TELA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TELA
- Reported as of
- 28 Jun 2024
- Net transaction value
- -$2,022,000
- SEC form
- 4
- Accepted by SEC
- 02 Jul 2024, 16:54:31 UTC
- Prior SEC filing
- 20 Jun 2024
- Next SEC filing
- 17 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ORBIMED ADVISORS LLC filed Form 4 for TELA Bio, Inc. (TELA) on 02 Jul 2024.
Change
- Previous filing in this sequence was filed on 20 Jun 2024.
- Current net transaction value: -$2,022,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TELA
transaction
Common Stock
Sale
- Transaction value
- $1,791,720
- Shares
- -378,000
- Change %
- -13%
- Price
- $4.74
- Shares after
- 2,457,542
- Date
- 28 Jun 2024
- Ownership
- See footnotes
- Footnotes
- F1, F2
TELA
transaction
Common Stock
Sale
- Transaction value
- $64,116
- Shares
- -13,700
- Change %
- -0.56%
- Price
- $4.68
- Shares after
- 2,443,842
- Date
- 01 Jul 2024
- Ownership
- See footnotes
- Footnotes
- F1, F2
TELA
transaction
Common Stock
Sale
- Transaction value
- $166,164
- Shares
- -36,600
- Change %
- -1.5%
- Price
- $4.54
- Shares after
- 2,407,242
- Date
- 02 Jul 2024
- Ownership
- See footnotes
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
ORBIMED ADVISORS LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP IV. By virtue of such relationships, OrbiMed Advisors and GP IV may be deemed to have voting power and investment power over the securities held by OPI IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI IV.
Footnote F2
Each of OrbiMed Advisors and GP IV disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.